E-LIB Suche - Ergebnisse für: Bataller, Alex

1

Therapy-related chronic myelomonocytic leukemia does not ha..:

Bataller, Alex ; Gener-Ricos, Georgina ; Almanza-Huante, Emmanuel...
Blood Advances. 8 (2024) 11 - p. 2695-2706 , 2024

Link: https://doi.org/10.1182/..

2

Reduced dose azacitidine plus venetoclax as maintenance the..:

Bazinet, Alexandre ; Kantarjian, Hagop ; Bataller, Alex...
The Lancet Haematology. 11 (2024) 4 - p. e287-e298 , 2024

Link: https://doi.org/10.1016/..

3

Oral decitabine and cedazuridine plus venetoclax for older ..:

Bazinet, Alexandre ; Garcia-Manero, Guillermo ; Short, Nicholas...
The Lancet Haematology. 11 (2024) 4 - p. e276-e286 , 2024

Link: https://doi.org/10.1016/..

4

Oral decitabine plus cedazuridine and venetoclax in patient..:

Bataller, Alex ; Montalban-Bravo, Guillermo ; Bazinet, Alexandre...
The Lancet Haematology. 11 (2024) 3 - p. e186-e195 , 2024

Link: https://doi.org/10.1016/..

5

Integrative single‐cell expression and functional studies u..:

Velasco‐Hernandez, Talia ; Trincado, Juan L. ; Vinyoles, Meritxell...
HemaSphere. 8 (2024) 2 - p. , 2024

Link: https://doi.org/10.1002/..

6

Prognostic risk signature in patients with acute myeloid le..:

Bataller, Alex ; Bazinet, Alexandre ; DiNardo, Courtney D....
Blood Advances. 8 (2024) 4 - p. 927-935 , 2024

Link: https://doi.org/10.1182/..

7

Targetable genetic abnormalities in patients with acute mye..:

Bataller, Alex ; DiNardo, Courtney D. ; Bazinet, Alexandre...
American Journal of Hematology. 99 (2024) 4 - p. 792-796 , 2024

Link: https://doi.org/10.1002/..

8

Outcomes and genetic dynamics of acute myeloid leukemia at ..:

Bataller, Alex ; Kantarjian, Hagop ; Bazinet, Alexandre...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

9

Characteristics and clinical outcomes of patients with myel..:

Bataller, Alex ; Loghavi, Sanam ; Gerstein, Yoheved...
American Journal of Hematology. 98 (2023) 11 - p. 1780-1790 , 2023

Link: https://doi.org/10.1002/..

10

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC..:

Urrutia, Samuel ; LI, Ziyi ; Almanza, Emmanuel...
HemaSphere. 7 (2023) S3 - p. e04859d5 , 2023

Link: https://doi.org/10.1097/..

11

Venetoclax with hypomethylating agents might lead to eradic..:

Jiménez-Vicente, Carlos ; Martínez-Roca, Alexandra ; Pomares, Helena...
Leukemia Research. 135 (2023) - p. 107403 , 2023

Link: https://doi.org/10.1016/..

12

Phase II study of cladribine, idarubicin, and ara‐C (CLIA) ..:

Kadia, Tapan M. ; Ravandi, Farhad ; Molica, Matteo...
American Journal of Hematology. 98 (2023) 11 - p. 1711-1720 , 2023

Link: https://doi.org/10.1002/..

13

PHF6 mutations in myelodysplastic syndromes, chronic myelom..:

Bataller, Alex ; Chien, Kelly S. ; Sasaki, Koji...
Leukemia Research. 127 (2023) - p. 107044 , 2023

Link: https://doi.org/10.1016/..

14

P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL ..:

Jimenez-Vicente, Carlos ; Guijarro, Francesca ; Lopez-Guerra, Monica...
HemaSphere. 7 (2023) S3 - p. e706751a , 2023

Link: https://doi.org/10.1097/..

15

Advancing CART therapy for acute myeloid leukemia: recent b..:

Pérez-Amill, Lorena ; Bataller, Àlex ; Delgado, Julio...
Frontiers in Immunology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..